Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Heat Biologics Inc (HTBX)

Heat Biologics Inc (HTBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,047
  • Shares Outstanding, K 25,650
  • Annual Sales, $ 2,110 K
  • Annual Income, $ -35,070 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.45
  • Price/Sales 28.77
  • Price/Cash Flow N/A
  • Price/Book 0.54
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.41
  • Most Recent Earnings $-0.54 on 03/14/22
  • Next Earnings Date 05/04/22
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/22
See More
  • Average Estimate $-0.46
  • Number of Estimates 1
  • High Estimate $-0.46
  • Low Estimate $-0.46
  • Prior Year $-0.31
  • Growth Rate Est. (year over year) -48.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.22 +7.20%
on 04/27/22
3.38 -29.59%
on 04/18/22
-0.71 (-22.98%)
since 04/01/22
3-Month
2.07 +14.98%
on 03/14/22
3.38 -29.59%
on 04/18/22
-0.40 (-14.39%)
since 02/02/22
52-Week
2.07 +14.98%
on 03/14/22
10.85 -78.06%
on 06/10/21
-4.49 (-65.36%)
since 04/30/21

Most Recent Stories

More News
NightHawk Biosciences Provides First Quarter 2022 Business Update

DURHAM, N.C., May 16, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on...

HTBX : 2.38 (+0.42%)
NHWK : 0.4135 (+8.96%)
Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today

DURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. / NightHawk Biosciences (NYSE American: HTBX; NHWK), a fully integrated...

HTBX : 2.38 (+0.42%)
Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021

DURHAM, NC / ACCESSWIRE / April 12, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including...

HTBX : 2.38 (+0.42%)
Heat Biologics Provides Year-End Business Update

DURHAM, NC / ACCESSWIRE / March 25, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including...

HTBX : 2.38 (+0.42%)
Heat Biologics to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

DURHAM, NC / ACCESSWIRE / March 8, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including...

HTBX : 2.38 (+0.42%)
Heat Biologics to Present at 2021 BIO CEO & Investor Digital Conference

DURHAM, NC / ACCESSWIRE / February 12, 2021 / Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...

HTBX : 2.38 (+0.42%)
Heat Biologics Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial

Median overall survival of 24.6 months in previously treated checkpoint inhibitor naïve non-small cell lung cancer patients who received HS-110 in combination with nivolumab DURHAM, NC / ACCESSWIRE /...

HTBX : 2.38 (+0.42%)

Business Summary

Heat Biologics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. The Company's products under development include HS-110 for the treatment of non-small cell...

See More

Key Turning Points

3rd Resistance Point 2.61
2nd Resistance Point 2.55
1st Resistance Point 2.46
Last Price 2.38
1st Support Level 2.31
2nd Support Level 2.25
3rd Support Level 2.16

See More

52-Week High 10.85
Fibonacci 61.8% 7.50
Fibonacci 50% 6.46
Fibonacci 38.2% 5.42
Last Price 2.38
52-Week Low 2.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.